REFERENCES
1.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Updated 17 May 2017]. Accessed 09/26/2019
2. Volpe M, Chin D, Paneni F. The challenge of polypharmacy in
cardiovascular medicine. Fundam Clin Pharmacol . 2010;24(1):9-17.
3. Khandeparkar A, Rataboli PV. A study of harmful drug–drug
interactions due to polypharmacy in hospitalized patients in Goa Medical
College. Perspect Clin Res . 2017;8(4):180.
4. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug
and herb-drug interactions in patients with cancer: A prospective study
of medication surveillance. J Oncol Pract . 2017;13(7):e613-e622.
5. Murtaza G, Khan MYG, Azhar S, Khan SA, Khan TM. Assessment of
potential drug–drug interactions and its associated factors in the
hospitalized cardiac patients. Saudi Pharmaceutical Journal .
2016;24(2):220-225.
6. Moura C, Prado N, Acurcio F. Potential drug-drug interactions
associated with prolonged stays in the intensive care unit. Clin
Drug Investig . 2011;31(5):309-316.
7. Shakeel F, Khan JA, Aamir M, Asim SM, Ullah I. A multicentered
pharmacoepidemiological approach to evaluate clinically significant
potential drug–drug interactions in medical intensive care settings in
Pakistan. Hong Kong Journal of Emergency Medicine .
2018;25(4):190-195. doi:10.1177/1024907918765510
8. Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in
cardiac and cardiothoracic intensive care units. Drug Saf .
2010;33(10):879-888.
9. Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug
interactions and its associated factors in a Brazilian teaching
hospital. Journal of Pharmacy and Pharmaceutical Sciences .
2006;9(3):427-433.
10. Zwart‐van Rijkom JE, Uijtendaal EV, Ten Berg MJ, Van Solinge WW,
Egberts AC. Frequency and nature of drug–drug interactions in a Dutch
university hospital. Br J Clin Pharmacol . 2009;68(2):187-193.
11. Shakeel F, Khan JA, Aamir M, Hannan PA, Zehra S, Ullah I. Risk of
potential drug-drug interactions in the cardiac intensive care units: A
comparative analysis between 2 tertiary care hospitals. Saudi Med
J . 2018;39(12):1207-1212.
12. Horn E, Jacobi J. The critical care clinical pharmacist: Evolution
of an essential team member. Crit Care Med . 2006;34(3):S46-S51.
doi:10.1097/01.Ccm.0000199990.68341.33
13. Urbina O, Ferrández O, Luque S, et al. Patient risk factors for
developing a drug-related problem in a cardiology ward. Ther Clin
Risk Manag . 2015;11:9-15.
14. Radley DC, Wasserman MR, Olsho LE, Shoemaker SJ, Spranca MD,
Bradshaw B. Reduction in medication errors in hospitals due to adoption
of computerized provider order entry systems. J Am Med Inform
Assoc . 2013;20(3):470-476. doi:10.1136/amiajnl-2012-001241
15. Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction
software in clinical practice: a systematic review. journal article.Eur J Clin Pharmacol . February 01 2015;71(2):131-142.
doi:10.1007/s00228-014-1786-7
16. Daniel WW, Cross CL. Biostatistics: a foundation for analysis
in the health sciences . Wiley Global Education; 2018.
17. Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL.
Comparison of nine tools for screening drug-drug interactions of Oral
Oncolytics. J Oncol Pract . 2018;14(6):e368-e374.
18. Reis AMM, Cassiani SHDB. Adverse drug events in an intensive care
unit of a university hospital. journal article. Eur J Clin
Pharmacol . June 01 2011;67(6):625-632. doi:10.1007/s00228-010-0987-y
19. Jain S, Jain P, Sharma K, Saraswat P. A prospective analysis of drug
interactions in patients of intensive cardiac care unit. Journal
of Clinical and Diagnostic Research: JCDR . 2017;11(3):FC01.
20. Baniasadi S, Farzanegan B, Alehashem M. Important drug classes
associated with potential drug–drug interactions in critically ill
patients: highlights for cardiothoracic intensivists. Annals of
intensive care . 2015;5(1):44.
21. Janković SM, Pejčić AV, Milosavljević MN, et al. Risk factors for
potential drug-drug interactions in intensive care unit patients.J Crit Care . 2018;43:1-6.
22. Carter BL, Lund BC, Hayase N, Chrischilles E. The extent of
potential antihypertensive drug interactions in a Medicaid population.Am J Hypertens . 2002;15(11):953-957.
doi:10.1016/s0895-7061(02)03026-1
23. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The
rising tide of polypharmacy and drug-drug interactions: population
database analysis 1995–2010. BMC Med . 2015/04/07 2015;13(1):74.
doi:10.1186/s12916-015-0322-7
24. Lima REF, Cassiani SHDB. Potential drug interactions in intensive
care patients at a teaching hospital. Rev Lat Am Enfermagem .
2009;17:222-227.
25. Sharma S, Chhetri HP, Alam K. A study of potential drug-drug
interactions among hospitalized cardiac patients in a teaching hospital
in Western Nepal. Indian J Pharmacol . 2014;46(2):152.
26. Scott IA, Pillans PI, Barras M, Morris C. Using EMR-enabled
computerized decision support systems to reduce prescribing of
potentially inappropriate medications: a narrative review.Therapeutic Advances in Drug Safety . 2018;9(9):559-573.
doi:10.1177/2042098618784809
27. Vinks THAM, Egberts TCG, de Lange TM, de Koning FHP.
Pharmacist-Based Medication Review Reduces Potential Drug-Related
Problems in the Elderly. journal article. Drugs Aging . February
01 2009;26(2):123-133. doi:10.2165/0002512-200926020-00004
28. Rivkin A, Yin H. Evaluation of the role of the critical care
pharmacist in identifying and avoiding or minimizing significant
drug-drug interactions in medical intensive care patients. J Crit
Care . 2011;26(1):104. e1-104. e6.
29. Maguire M, Franz T, Hains DS. A clinically significant interaction
between tacrolimus and multiple proton pump inhibitors in a kidney
transplant recipient. Pediatr Transplant . 2012;16(6):E217-E220.
30. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood
concentrations and efficacy and toxicity after liver and kidney
transplantation. Br J Clin Pharmacol . 1996;62(7):920-926.
31. Payne TH, Hines LE, Chan RC, et al. Recommendations to improve the
usability of drug-drug interaction clinical decision support alerts.J Am Med Inform Assoc . 2015;22(6):1243-1250.